"Fortis Escorts Heart Institute has set benchmarks in cardiac care with Paediatric path breaking work over the past 32 years. Today, it is recognised world over as a centre of excellence providing the latest technology in Cardiac Bypass Surgery, Interventional Cardiology, Non-invasive Cardiology, Paediatric Cardiology and Paediatric Cardiac Surgery. The hospital is backed by the most advanced laboratories performing complete range of investigative tests in the field of Nuclear Medicine, Radiology, Biochemistry, Haematology, Transfusion Medicine and Microbiology."

During the past decade, Fortis Escorts Heart Institute conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 8 clinical trials were completed, i.e. on average, 61.5% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 5 clinical trials were completed. i.e. 250% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Fortis Escorts Heart Institute" #1 sponsor was "Abbott Medical Devices" with 6 trials, followed by "Boehringer Ingelheim" with 4 trials sponsored, "Medtronic Cardiac Rhythm and Heart Failure" with 3 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored and "BIOTRONIK Asia Pacific Pte Ltd" with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Fortis Escorts Heart Institute" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "Boston Scientific Corporation" with 1 trials as a collaborator, "Indian Society of Critical Care Medicine" with 1 trials as a collaborator, "Max Neeman Medical International Ltd." with 1 trials as a collaborator and "Medtronic" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Fortis Escorts Heart Institute" are "Coronary Artery Disease" (5 trials), "Heart Failure" (3 trials), "Myocardial Ischemia" (3 trials), "Acute Myocardial Infarction" (2 trials) and "Atrial Fibrillation" (2 trials). Many other conditions were trialed in "Fortis Escorts Heart Institute" in a lesser frequency.

Most popular intervention types in "Fortis Escorts Heart Institute" are "Device" (9 trials), "Drug" (7 trials), "Other" (3 trials), "Behavioral" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Empagliflozin" (2 trials), "ABSORB BVS" (1 trials), "Aspirin" (1 trials) and "Autologous Bone marrow mononuclear cells" (1 trials). Other intervention names were less common.

The vast majority of trials in "Fortis Escorts Heart Institute" are 23 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Fortis Escorts Heart Institute". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Fortis Escorts Heart Institute, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Fortis Escorts Heart Institute, 2 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 7 trials that are defined as “Not Applicable".